BioPharma Dive September 24, 2024
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that’s administered monthly. Elsewhere, Sanofi invested in a struggling biotech and Novartis inked a research pact.
Today, a brief rundown of news from Metsera and Novartis, as well as updates from Sanofi and Wave Life Sciences that you may have missed.
Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097, that’s designed to have longer-lasting effects than injectable GLP-1 therapies like Novo Nordisk’s Wegovy. The results show that a weekly administration of the highest dose tested stimulated weight loss of 7.5% over 36...
Today's Sponsors
Today's Sponsor